Literature DB >> 21289438

Proteomic analysis of cell lines to identify the irinotecan resistance proteins.

Xing-Chen Peng1, Feng-Ming Gong, Meng Wei, Xi Chen, Ye Chen, Ke Cheng, Feng Gao, Feng Xu, Feng Bi, Ji-Yan Liu.   

Abstract

Chemotherapeutic drug resistance is a frequent cause of treatment failure in colon cancer patients. Several mechanisms have been implicated in drug resistance. However, they are not sufficient to exhaustively account for this resistance emergence. In this study, two-dimensional gel electrophoresis (2-DE) and the PDQuest software analysis were applied to compare the differential expression of irinotecan-resistance-associated protein in human colon adenocarcinoma LoVo cells and irinotecan-resistant LoVo cells (LoVo/irinotecan). The differential protein dots were excised and analysed by ESI-Q-TOF mass spectrometry (MS). Fifteen proteins were identified, including eight proteins with decreased expression and seven proteins with increased expression. The identified known proteins included those that function in diverse biological processes such as cellular transcription, cell apoptosis, electron transport/redox regulation, cell proliferation/differentiation and retinol metabolism pathways. Identification of such proteins could allow improved understanding of the mechanisms leading to the acquisition of chemoresistance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21289438     DOI: 10.1007/s12038-010-0064-9

Source DB:  PubMed          Journal:  J Biosci        ISSN: 0250-5991            Impact factor:   1.826


  29 in total

Review 1.  Multidrug resistance: molecular mechanisms and clinical relevance.

Authors:  V Ling
Journal:  Cancer Chemother Pharmacol       Date:  1997       Impact factor: 3.333

Review 2.  Aldo-keto reductases and bioactivation/detoxication.

Authors:  Yi Jin; Trevor M Penning
Journal:  Annu Rev Pharmacol Toxicol       Date:  2007       Impact factor: 13.820

Review 3.  Proteomic technologies and their application to pancreatic cancer.

Authors:  Dale Vimalachandran; Eithne Costello
Journal:  Expert Rev Proteomics       Date:  2004-12       Impact factor: 3.940

Review 4.  Proteomic profiling of pancreatic cancer for biomarker discovery.

Authors:  Ru Chen; Sheng Pan; Teresa A Brentnall; Ruedi Aebersold
Journal:  Mol Cell Proteomics       Date:  2005-01-31       Impact factor: 5.911

5.  Transport of amphipathic anions by human multidrug resistance protein 3.

Authors:  H Zeng; G Liu; P A Rea; G D Kruh
Journal:  Cancer Res       Date:  2000-09-01       Impact factor: 12.701

6.  Doxorubicin metabolism and toxicity in human myocardium: role of cytoplasmic deglycosidation and carbonyl reduction.

Authors:  S Licata; A Saponiero; A Mordente; G Minotti
Journal:  Chem Res Toxicol       Date:  2000-05       Impact factor: 3.739

7.  Comparative activity of anthracycline 13-dihydrometabolites against rat glioblastoma cells in culture.

Authors:  B Schott; J Robert
Journal:  Biochem Pharmacol       Date:  1989-11-15       Impact factor: 5.858

Review 8.  Multiplicity of mammalian reductases for xenobiotic carbonyl compounds.

Authors:  Toshiyuki Matsunaga; Shinichi Shintani; Akira Hara
Journal:  Drug Metab Pharmacokinet       Date:  2006-02       Impact factor: 3.614

9.  Cancer statistics, 2009.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2009-05-27       Impact factor: 508.702

10.  alphaB-crystallin: a novel p53-target gene required for p53-dependent apoptosis.

Authors:  Gou Watanabe; Shunsuke Kato; Hideyuki Nakata; Takanori Ishida; Noriaki Ohuchi; Chikashi Ishioka
Journal:  Cancer Sci       Date:  2009-08-18       Impact factor: 6.716

View more
  5 in total

Review 1.  Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy?

Authors:  Richard Callaghan; Frederick Luk; Mary Bebawy
Journal:  Drug Metab Dispos       Date:  2014-02-03       Impact factor: 3.922

2.  Regulation of aldo-keto reductases in human diseases.

Authors:  Wei-Dong Chen; Yanqiao Zhang
Journal:  Front Pharmacol       Date:  2012-03-09       Impact factor: 5.810

3.  RhoA regulates resistance to irinotecan by regulating membrane transporter and apoptosis signaling in colorectal cancer.

Authors:  Huang Ruihua; Zhang Mengyi; Zhao Chong; Qiu Meng; Ma Xin; Tang Qiulin; Bi Feng; Liu Ming
Journal:  Oncotarget       Date:  2016-12-27

Review 4.  Irinotecan-Still an Important Player in Cancer Chemotherapy: A Comprehensive Overview.

Authors:  Mateusz Kciuk; Beata Marciniak; Renata Kontek
Journal:  Int J Mol Sci       Date:  2020-07-12       Impact factor: 5.923

Review 5.  Aldo-Keto Reductases and Cancer Drug Resistance.

Authors:  Trevor M Penning; Sravan Jonnalagadda; Paul C Trippier; Tea Lanišnik Rižner
Journal:  Pharmacol Rev       Date:  2021-07       Impact factor: 18.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.